Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2DLhjyH